Jafron Biomedical Co

Jafron Biomedical Co Operating Expenses

The Total Operating Expenses of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 475.37 M CNY. In the previous year, Total Operating Expenses was 429.29 M CNY — a change of 10.73% (higher).

Operating Expenses

475.37 MCNY

YoY

10.73%

Last updated:

Total Operating Expenses of Jafron Biomedical Co is 2025 475.37 M CNY. Total Operating Expenses of Jafron Biomedical Co was 2024 429.29 M CNY. It decreases by 10.73% higher compared to the previous year.

The Jafron Biomedical Co Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
133.14 M CNY
Jan 1, 2019
179.72 M CNY
Jan 1, 2020
199.77 M CNY
Jan 1, 2021
304.74 M CNY
Jan 1, 2022
392.05 M CNY
Jan 1, 2023
422.76 M CNY
Jan 1, 2024
429.29 M CNY
Jan 1, 2025
475.37 M CNY
The Jafron Biomedical Co Operating Expenses history
YEAROperating ExpensesYoY
475.37 MCNY+10.73%
429.29 MCNY+1.54%
422.76 MCNY+7.83%
392.05 MCNY+28.65%
304.74 MCNY+52.55%
199.77 MCNY+11.16%
179.72 MCNY+34.99%
133.14 MCNY+41.93%
93.80 MCNY+4.22%
90.01 MCNY+17.32%
76.72 MCNY+30.35%
58.86 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Total Operating Expenses of Jafron Biomedical Co is 475.37 M CNY in 2025.

Total Operating Expenses of Jafron Biomedical Co changed from 429.29 M CNY to 475.37 M CNY, representing a 10.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Jafron Biomedical Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Jafron Biomedical Co